Alignment Healthcare, Inc. (ALHC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong financial performance with increased EBITDA and revenue, positive free cash flow, and improved operational efficiency. While SG&A increased, it declined as a percentage of revenue. Optimistic guidance and strategic market positioning, including AI investments and strong provider relationships, further support a positive outlook. The company's low exposure to risk model rebasing and proactive approach to regulatory changes enhance confidence. The market cap suggests moderate sensitivity to these positive developments, leading to a likely positive stock price movement over the next two weeks.
Key Financial Performance
Health Plan Membership 236,300 members in 2025, representing a 25% year-over-year growth. This growth was attributed to the company's clinically centric model and operational advantages.
Total Revenue (Q4 2025) $1 billion, a 44% year-over-year increase. The growth was driven by increased membership and operational efficiency.
Adjusted Gross Profit (Q4 2025) $125 million with an adjusted MBR of 87.7%. This exceeded guidance expectations.
Adjusted EBITDA (Q4 2025) $11 million, surpassing the guidance range of negative $9 million to negative $1 million.
Total Revenue (Full Year 2025) $3.9 billion, a 46% year-over-year increase. Growth was driven by membership expansion and operational efficiency.
Adjusted Gross Profit (Full Year 2025) $495 million with an MBR of 87.5%, an improvement of 130 basis points year-over-year. This was due to strong outcomes in medical cost categories and proactive care approaches.
Adjusted EBITDA (Full Year 2025) $110 million, reflecting a 2.8% margin and a 270 basis points margin expansion year-over-year. This was attributed to operational efficiency and scaling.
Adjusted SG&A (Full Year 2025) $385 million, a 28% year-over-year increase. However, as a percentage of revenue, it declined from 11.1% in 2024 to 9.7% in 2025, showing a 140 basis points improvement due to operational scaling.
Free Cash Flow (2025) Positive free cash flow was generated, and the company ended the year with $604 million in cash and investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AIVA technology platform and Care Anywhere clinical model: These platforms provided visibility and control, enabling the company to navigate disruptions and deliver high-quality care at low costs.
Ex-California membership growth: Membership outside California more than doubled, reaching approximately 38,000 members, representing 16% of total membership. The company achieved high star ratings in multiple states, including North Carolina, Nevada, Texas, and Arizona.
2026 membership growth: Health plan membership is expected to grow to 292,000-298,000 members, with significant growth outside California (80% growth in ex-California counties).
Operational efficiency improvements: Adjusted SG&A as a percentage of revenue declined from 11.1% in 2024 to 9.7% in 2025, showing a 140 basis point improvement. Investments in AI workflows are planned to enhance administrative efficiency.
Adjusted EBITDA growth: Adjusted EBITDA grew from $1 million in 2024 to $110 million in 2025, with a margin expansion of 270 basis points year-over-year.
Expansion strategy: The company is focusing on growing responsibly through bid design and sales strategy, while investing in sales, distribution, and broker relationships to sustain momentum in ex-California markets.
AI and scalability initiatives: Investments in AI workflows and technology infrastructure are planned to improve administrative efficiency and prepare for scaling the business.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
V28 Risk Model Phase-In: The company faced challenges due to the second phase of the V28 risk model in 2025 and anticipates further impact from the final phase-in during 2026. This could affect revenue and profitability as adjustments are made to align with the new reimbursement environment.
Regulatory Adjustments: Policy changes, such as those related to skin substitutes and unlinked chart reviews, could impact reimbursement rates and operational processes. Although the company has limited exposure to unlinked chart reviews, these changes require adjustments to ensure compliance and maintain revenue integrity.
Expansion Outside California: While the company has seen growth in markets outside California, these regions carry modestly lower per-member revenue. Additionally, the company faces challenges in scaling its clinical model and operations to new markets while maintaining profitability and quality of care.
High-Risk Member Mix: The company’s growth strategy includes enrolling more high-risk members, such as LIS, dual eligible, and C-SNP eligible members. These members typically have higher medical benefit ratios (MBRs) in their first year, which could pressure margins and require significant care management resources.
Economic and Industry Disruptions: Broad utilization pressures across the Medicare Advantage industry and economic uncertainties could impact the company’s cost structure and ability to maintain profitability.
Operational Efficiency and Scalability: The company plans to invest in AI workflows and other scalability initiatives, but these investments carry execution risks and may not yield the expected efficiency gains or cost savings in the short term.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Health Plan Membership Growth: For 2026, health plan membership is expected to be between 292,000 and 298,000 members, representing significant growth from 2025. Membership for the first quarter of 2026 is projected to be between 281,000 and 285,000 members.
Revenue Projections: Revenue for 2026 is expected to be in the range of $5.14 billion to $5.19 billion, with first-quarter revenue projected between $1.21 billion and $1.23 billion. This represents a 31% year-over-year growth.
Adjusted Gross Profit: For 2026, adjusted gross profit is projected to be between $615 million and $650 million, with a midpoint implying an MBR of 87.7%. First-quarter adjusted gross profit is expected to be between $138 million and $148 million.
Adjusted EBITDA: The company expects adjusted EBITDA for 2026 to be in the range of $133 million to $163 million, consistent with prior expectations. First-quarter adjusted EBITDA is projected to be between $26 million and $36 million.
Market Expansion and Growth Strategy: The company plans to invest in sales and distribution, broker relationships, and aligned provider partnerships to sustain momentum in markets outside California. With less than 4% market share in 23 counties outside California, there is significant growth potential.
Operational Efficiency and Investments: The company aims to improve operating efficiency and reinvest savings into clinical model advancements, new market activities, and technology infrastructure, including AI workflows to enhance administrative efficiency.
2027 Advanced Rate Notice and Reimbursement Environment: The company anticipates a relatively flat rate environment for 2027, with continued growth in costs within the fee-for-service population. The reimbursement environment is expected to create a level playing field, benefiting the company's clinically led model and cost management capabilities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What would prevent Alignment in '27 from having a rerun of what was accomplished in '24 or '25?
A:John Kao stated that the model is working irrespective of the rate environment and that Alignment will continue to be disciplined in balancing growth and margin expansion. He emphasized the importance of durable provider relationships and operational improvements, including AI deployment, to sustain growth over the next 3-4 years.
Q:What are the assumptions embedded in the implied MLR for '26?
A:James Head explained that the 2026 guide is based on three core inputs: 2025 experience, disciplined growth in specific markets, and the absence of a sweep payment. He noted that new members, particularly Dual-Eligible and C-SNP members, come with higher MBR initially but offer long-term opportunities. Part D performance also contributes to the overall mix.
Q:How is Alignment thinking about changes to its distribution network and broker community?
A:John Kao mentioned that Alignment is focusing on deeper relationships with brokers and providers, particularly in ex-California markets and potential new states. He emphasized the importance of brokers in the distribution strategy and stated that new market entry is not dependent on rate changes.
Q:What is Alignment's perspective on the RFI from CMS and potential incremental changes?
A:John Kao stated that Alignment submitted comments and supports program integrity measures like documentation of HRAs. He emphasized the importance of beneficiary choice and expressed confidence in Alignment's ability to adapt to any changes.
Q:What drove the favorability in the 80k metric in Q4, and what is the outlook for '26?
A:James Head attributed the favorable Q4 results to a mild flu season and noted that the 80k metric might tick up slightly in '26 due to member mix. He emphasized that seasonal trends will likely follow historical patterns.
Q:What are the current AI investments and their expected benefits?
A:John Kao highlighted ongoing efforts to improve data architecture and workflows to enable scalable AI deployment. He mentioned potential use cases in member services, financial reporting, and administrative improvements, with a focus on achieving cash flow breakeven faster and enhancing Stars and benefits.
Q:Is the DMA industry losing bipartisan support in Washington, and what can be done to improve its standing?
A:John Kao emphasized the importance of returning to CMS's original intent for MA, focusing on high quality and low cost. He noted that financial engineering practices like coding and prior authorization are unsustainable and that MA's value proposition will drive continued growth.
Q:What is Alignment's view on the final rate notice for '27 and its potential impact?
A:John Kao expressed hope that CMS will address issues like skin substitutes and provide a reasonable rate increase. He noted that Alignment is well-positioned to succeed regardless of rate changes due to its high-quality, low-cost model.
Q:What is Alignment's exposure to chart reviews and risk model rebasing?
A:John Kao stated that Alignment's exposure to chart reviews is minimal, at about 1%, and that the company is less exposed to risk model rebasing compared to others due to its lower blended RAF scores.
Q:How is Alignment engaging new members through the Care Anywhere platform?
A:John Kao reported that engagement levels are consistent with the previous year at about 65%, with a target to increase to 75%. He highlighted ongoing efforts to improve member services and experience.
Q:What are the operational nuances in ex-California markets, and how is Alignment addressing them?
A:John Kao acknowledged the need for better provider engagement and operational scaling to ensure consistent service levels across markets. He emphasized the importance of provider satisfaction metrics and clinical replicability.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about the specific growth rate CMS should adopt for '27, stating only that they hope for a reasonable rate increase. Additionally, they did not provide precise details on the split within the 1% exposure to chart reviews, citing its immateriality.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AEP disenrollment
AI workflow
Admired Companies
Anywhere model
Arizona achievement
CEO Head
CEO conference
California county
California expansion
California membership
California opportunity
California potential
California quality
Care Anywhere
Carolina star
Companies model
Conference Instructions
Form measure
Fortune Magazine
HCC value
chart review
disruption
efficiency
environment industry
market California
member market
model care
partner
path
policy
program integrity
rate environment
scalability
share
star plan
step
success
ALHC Transcript
Alignment Healthcare, Inc. (ALHC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Alignment Healthcare, Inc. (ALHC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Alignment Healthcare, Inc. (ALHC) Q1 2026 Earnings Call Transcript
Positive5-1
The earnings call summary reveals strong financial metrics and optimistic guidance, with significant revenue growth and market expansion plans. Despite some concerns over inpatient issues, management has addressed these, and the guidance reflects confidence. The Q&A section indicates that analysts are satisfied with management's responses, and there is optimism about the company's strategic plans, including market expansion and operational efficiency improvements. Given the market cap of approximately $1.5 billion, these positive factors are likely to result in a stock price increase of 2% to 8% over the next two weeks.
Alignment Healthcare, Inc. (ALHC) Q4 2025 Earnings Call Transcript
Positive2-27
The earnings call summary and Q&A indicate strong financial performance with increased EBITDA and revenue, positive free cash flow, and improved operational efficiency. While SG&A increased, it declined as a percentage of revenue. Optimistic guidance and strategic market positioning, including AI investments and strong provider relationships, further support a positive outlook. The company's low exposure to risk model rebasing and proactive approach to regulatory changes enhance confidence. The market cap suggests moderate sensitivity to these positive developments, leading to a likely positive stock price movement over the next two weeks.
ALHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
